Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma

49Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

The most common subtype of renal cell carcinoma (RCC) is clear cell RCC (ccRCC). It accounts for 70-80% of all renal malignancies representing the third most common urological cancer after prostate and bladder cancer. The identification of non-invasive biomarkers for the diagnosis and responsiveness to therapy of ccRCC may represent a relevant step-forward in ccRCC management. The aim of this study is to evaluate whether specific miRNAs deregulated in ccRCC tissues present altered levels also in urine specimens. To this end we first assessed that miR-21-5p, miR-210-3p and miR-221-3p resulted upregulated in ccRCC fresh frozen tissues compared to matched normal counterparts. Next, we evidenced that miR-210-3p resulted significantly upregulated in 38 urine specimens collected from two independent cohorts of ccRCC patients at the time of surgery compared to healthy donors samples. Of note, miR- 210-3p levels resulted significantly reduced in follow-up samples. These results point to miR-210-3p as a potential non-invasive biomarker useful not only for diagnosis but also for the assessment of complete resection or response to treatment in ccRCC management.

Cite

CITATION STYLE

APA

Petrozza, V., Pastore, A. L., Palleschi, G., Tito, C., Porta, N., Ricci, S., … Fazi, F. (2017). Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma. Oncotarget, 8(41), 69551–69558. https://doi.org/10.18632/oncotarget.18449

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free